Amira Pharmaceuticals’ LPA1 receptor antagonist plan data published in Uk Journal of Pharmacology Amira Pharmaceuticals, Inc. Announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology. The data in this publication demonstrate the potential of a higher affinity, oral antagonist of the LPA1 receptor in illnesses associated with fibrosis, edema and inflammation, stated James Swaney, Ph type 2 diabetes .D., Senior Scientist at Amira and the senior author of the paper. Bob Baltera, Chief Executive Officer of Amira, added, We are centered on developing LPA1 antagonists in fibrotic illnesses. .

drug effects

Amorfix, Epitomics collaborate to build up high-affinity monoclonal antibodies against cancer tumor targets Amorfix Lifestyle Sciences and Epitomics, Inc. Announced today they have entered into an agreement to build up high-affinity monoclonal antibodies against numerous targets for malignancy. Amorfix has identified many disease specific epitopes on misfolded proteins with their proprietary ProMIS computational platform discovery technology, which is used by Epitomics to create highly particular monoclonal antibodies . Epitomics, together with its partners, has successfully generated over a dozen humanized therapeutic antibody medication leads targeting immune diseases and cancers using RabMAb technology and its own proprietary Mutation Lineage Guided humanization technology.